AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00909480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued
Study NCT00909480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued
Study NCT00861601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 12.5 milligrams (mg) tablet
Description: eltrombopag 12.5 mg tablet once a day
Study NCT00861601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 25 mg tablet
Description: eltrombopag 25 mg tablet once a day
Study NCT00006002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00006002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study NCT00329537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Self-subcutaneous injection
Study NCT00329537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-subcutaneous injection
Study NCT03128177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Description: High (6 g) versus low (1.5 g) sodium diet
Study NCT00136136 — intervention group
Intervention type: PROCEDURE
Intervention: Registration of the bispectral index and spectral edge frequency
Description: Registration of the bispectral index and spectral edge frequency
Study NCT01120158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
Study NCT01120158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
Study NCT03911427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active oat beverage
Description: Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
Study NCT03911427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control rice beverage
Description: Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg tablets
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100 mg tablets
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 500 mg tablets
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
Study NCT03338621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: isoniazid 75 mg plus rifampicin 150 mg combination tablets
Study NCT03113123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PrEP with Truvada®
Description: Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.
Study NCT03940963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AxoGuard® Nerve Cap
Description: Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
Study NCT03940963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Neurectomy
Description: Surgical excision of symptomatic neuroma
Study NCT02080104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intarvenous and intramusculer 10 IU oxytocin
Description: intarvenous and intramusculer 10 IU oxytocin
Study NCT02080104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intarvenous and intramusculer 10 IU oxytocin
Description: intarvenous and intramusculer 10 IU oxytocin
Study NCT02013336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Description: chemotherapy
Study NCT01682993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topography guided Excimer Laser treatment and Corneal Cross Linking
Description: A topography guided excimer laser treatment will be performed prior to CCL in one session.
Study NCT01682993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking
Description: A standard corneal cross linking procedure will be performed in this arm.
Study NCT02635074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02635074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02635074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT01148862 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The MiniMed Paradigm® X54 System
Description: The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends.
Study NCT00621868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral
Study NCT04531371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis
Study NCT03211897 — intervention group
Intervention type: DRUG
Intervention: Haloperidol Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study NCT00621868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02939300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Melanoma:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.
Study NCT02939300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: * Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses
Study NCT00535782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Administered by intravenous infusion, 8 mg/kg every 4 weeks.
Study NCT00535782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Administered by intravenous infusion, 8 mg/kg every 4 weeks.
Study NCT00535782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
Study NCT00535782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally or parenterally, 7.5-25 mg weekly.
Study NCT00535782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally or parenterally, 7.5-25 mg weekly.
Study NCT02023411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
Study NCT02023411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04257123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Participants will administer Gelesis100 before lunch and dinner meals.
Study NCT04352166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release buprenorphine (BXR)
Description: Three monthly injections will be provided during the course of the 12 week trial.
Study NCT04352166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual buprenorphine (BSL)
Description: On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
Study NCT02123758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study NCT02123758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study NCT02123758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study NCT01209871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Description: Given ID
Study NCT01209871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03593590 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
Study NCT04257123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will administer a placebo before lunch and dinner meals.
Study NCT03643601 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
Study NCT00585832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH-4-Teens
Description: 24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
Study NCT02974881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
Study NCT01908465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebastine
Study NCT01908465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03211897 — intervention group
Intervention type: DRUG
Intervention: Ziprasidone Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study NCT02721576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
Study NCT03211897 — intervention group
Intervention type: DRUG
Intervention: OLANZapine Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study NCT03211897 — intervention group
Intervention type: DRUG
Intervention: Midazolam injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
Study NCT01490125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
Study NCT00585832 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
Study NCT01983943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol, the active ingredient in olive oil.
Description: A 40mg capsule will be taken once daily for 6 months.
Study NCT01983943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 40mg placebo will be taken once per day for 6 months.
Study NCT01983943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Nutrition counseling on eating a healthy diet will be offered once at baseline.
Study NCT01983943 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition counseling on eating a healthy diet will be offered once at baseline.
Study NCT01983943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopat
Description: An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
Study NCT01983943 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endopat
Description: An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
Study NCT00003620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00003620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04056845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valgus knee brace (Medex K39-OA Corrector)
Description: Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
Study NCT04056845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and oral analgesic (diclofenac and panadol)
Description: Physiotherapy and oral analgesic (diclofenac and panadol)
Study NCT04056845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and oral analgesic (diclofenac and panadol)
Description: Physiotherapy and oral analgesic (diclofenac and panadol)
Study NCT00714012 — intervention group
Intervention type: OTHER
Intervention: observational
Description: presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
Study NCT01639404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Administration
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
Study NCT01639404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study NCT02038855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Intervention for Dual Problems and Early Action
Description: Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
Study NCT03441802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High quality extra virgin olive oil
Description: Cases and controls were given 40 g/die high quality extra virgin olive oil
Study NCT03441802 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High quality extra virgin olive oil
Description: Cases and controls were given 40 g/die high quality extra virgin olive oil
Study NCT00278070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine oral formulation
Description: Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients are given 10 mg/kg IV Q2 weeks.
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Patients are given 10 mg/kg IV Q2 weeks.
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tarceva
Description: Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.